RISS 학술연구정보서비스

검색
다국어 입력

http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.

변환된 중국어를 복사하여 사용하시면 됩니다.

예시)
  • 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
  • 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
닫기
    인기검색어 순위 펼치기

    RISS 인기검색어

      SCIE SCOPUS KCI등재

      Increased Circulating CXCL10 in Non-Segmental Vitiligo Concomitant with Autoimmune Thyroid Disease and Alopecia Areata = Increased Circulating CXCL10 in Non-Segmental Vitiligo Concomitant with Autoimmune Thyroid Disease and Alopecia Areata

      한글로보기

      https://www.riss.kr/link?id=A106301852

      • 0

        상세조회
      • 0

        다운로드
      서지정보 열기
      • 내보내기
      • 내책장담기
      • 공유하기
      • 오류접수

      부가정보

      다국어 초록 (Multilingual Abstract)

      Background: Vitiligo is a common acquired pigmentary disease caused by destruction of epidermal melanocytes in underlying autoimmune response. Few studies have been focused on the role of chemokines in non-segmental vitiligo (NSV) concomitant with autoimmune thyroid disease (AITD) and alopecia areata (AA). Objective: The aim of this study was to determine the best serum biomarker for predictive role in the progression of vitiligo and to evaluate the influence of AA and/or AITD on vitiligo by using the biomarker. Methods: This prospective cohort study recruited 45 NSV patients: 14 without either AITD or AA, 12 with AITD, 11 with AA, and 8 with both AITD and AA. Serum levels of CXCL1, CXCL8, CXCL9, CXCL10, CXCL12, CXCL13, and CXCL16 were analyzed by ELISA. CXCR3 mRNA expression was detected on PBMCs by RT-PCR. Improvement was evaluated using repigmentation scales. Results: Serum CXCL10 levels, along with the expression of CXCR3 mRNA were higher in NSV patients with AITD or AA alone than in those without AITD or AA. Moreover, serum CXCL10 levels, along with the expression of CXCR3 mRNA were higher in NSV patients with both AITD and AA than in those with AITD or AA alone. Poorer repigmentation was observed in NSV patients with both AA and AITD than in those with AA or AITD alone. Conclusion: CXCL10 could be a biomarker to predict the progression of NSV. Dermatologists should pay much attention to those NSV patients concomitant with AITD and/or AA, for comorbidity might lead to more active autoimmune reaction. (Ann Dermatol 31(4) 393∼402, 2019)
      번역하기

      Background: Vitiligo is a common acquired pigmentary disease caused by destruction of epidermal melanocytes in underlying autoimmune response. Few studies have been focused on the role of chemokines in non-segmental vitiligo (NSV) concomitant with aut...

      Background: Vitiligo is a common acquired pigmentary disease caused by destruction of epidermal melanocytes in underlying autoimmune response. Few studies have been focused on the role of chemokines in non-segmental vitiligo (NSV) concomitant with autoimmune thyroid disease (AITD) and alopecia areata (AA). Objective: The aim of this study was to determine the best serum biomarker for predictive role in the progression of vitiligo and to evaluate the influence of AA and/or AITD on vitiligo by using the biomarker. Methods: This prospective cohort study recruited 45 NSV patients: 14 without either AITD or AA, 12 with AITD, 11 with AA, and 8 with both AITD and AA. Serum levels of CXCL1, CXCL8, CXCL9, CXCL10, CXCL12, CXCL13, and CXCL16 were analyzed by ELISA. CXCR3 mRNA expression was detected on PBMCs by RT-PCR. Improvement was evaluated using repigmentation scales. Results: Serum CXCL10 levels, along with the expression of CXCR3 mRNA were higher in NSV patients with AITD or AA alone than in those without AITD or AA. Moreover, serum CXCL10 levels, along with the expression of CXCR3 mRNA were higher in NSV patients with both AITD and AA than in those with AITD or AA alone. Poorer repigmentation was observed in NSV patients with both AA and AITD than in those with AA or AITD alone. Conclusion: CXCL10 could be a biomarker to predict the progression of NSV. Dermatologists should pay much attention to those NSV patients concomitant with AITD and/or AA, for comorbidity might lead to more active autoimmune reaction. (Ann Dermatol 31(4) 393∼402, 2019)

      더보기

      참고문헌 (Reference)

      1 McElwee KJ, "What causes alopecia areata" 22 : 609-626, 2013

      2 Picardo M, "Vitiligo" 1 : 15011-, 2015

      3 Rork JF, "Understanding autoimmunity of vitiligo and alopecia areata" 28 : 463-469, 2016

      4 Fröhlich E, "Thyroid autoimmunity : role of antithyroid antibodies in thyroid and extra-thyroidal diseases" 8 : 521-, 2017

      5 Vrijman C, "The prevalence of thyroid disease in patients with vitiligo : a systematic review" 167 : 1224-1235, 2012

      6 Taïeb A, "The definition and assessment of vitiligo : a consensus report of the Vitiligo European Task Force" 20 : 27-35, 2007

      7 Miniati A, "Stimulated human melanocytes express and release interleukin-8, which is inhibited by luteolin : relevance to early vitiligo" 39 : 54-57, 2014

      8 Lee HT, "Serum BLC/CXCL13 concentrations and renal expression of CXCL13/CXCR5 in patients with systemic lupus erythematosus and lupus nephritis" 37 : 45-52, 2010

      9 Stinco G, "Serological screening for autoimmune polyendocrine syndromes in patients with vitiligo" 26 : 1041-1042, 2012

      10 Speeckaert R, "S100B is a potential disease activity marker in nonsegmental vitiligo" 137 : 1445-1453, 2017

      1 McElwee KJ, "What causes alopecia areata" 22 : 609-626, 2013

      2 Picardo M, "Vitiligo" 1 : 15011-, 2015

      3 Rork JF, "Understanding autoimmunity of vitiligo and alopecia areata" 28 : 463-469, 2016

      4 Fröhlich E, "Thyroid autoimmunity : role of antithyroid antibodies in thyroid and extra-thyroidal diseases" 8 : 521-, 2017

      5 Vrijman C, "The prevalence of thyroid disease in patients with vitiligo : a systematic review" 167 : 1224-1235, 2012

      6 Taïeb A, "The definition and assessment of vitiligo : a consensus report of the Vitiligo European Task Force" 20 : 27-35, 2007

      7 Miniati A, "Stimulated human melanocytes express and release interleukin-8, which is inhibited by luteolin : relevance to early vitiligo" 39 : 54-57, 2014

      8 Lee HT, "Serum BLC/CXCL13 concentrations and renal expression of CXCL13/CXCR5 in patients with systemic lupus erythematosus and lupus nephritis" 37 : 45-52, 2010

      9 Stinco G, "Serological screening for autoimmune polyendocrine syndromes in patients with vitiligo" 26 : 1041-1042, 2012

      10 Speeckaert R, "S100B is a potential disease activity marker in nonsegmental vitiligo" 137 : 1445-1453, 2017

      11 Rotondi M, "Role of chemokines in endocrine autoimmune diseases" 28 : 492-520, 2007

      12 Liu M, "Rethinking screening for thyroid autoimmunity in vitiligo" 75 : 1278-1280, 2016

      13 Li S, "Oxidative stress drives CD8+ T-cell skin trafficking in patients with vitiligo through CXCL16 upregulation by activating the unfolded protein response in keratinocytes" 140 : 177-189, 2017

      14 Spritz RA, "Novel vitiligo susceptibility loci on chromosomes 7(AIS2)and 8(AIS3), confirmation of SLEV1 on chromosome 17, and their roles in an autoimmune diathesis" 74 : 188-191, 2004

      15 Gilhar A, "Lymphocytes, neuropeptides, and genes involved in alopecia areata" 117 : 2019-2027, 2007

      16 Richmond JM, "Keratinocyte-derived chemokines orchestrate T-cell positioning in the epidermis during vitiligo and may serve as biomarkers of disease" 137 : 350-358, 2017

      17 Nanba T, "Increases of the Th1/Th2 cell ratio in severe Hashimoto's disease and in the proportion of Th17 cells in intractable Graves' disease" 19 : 495-501, 2009

      18 Wang XX, "Increased expression of CXCR3 and its ligands in patients with vitiligo and CXCL10 as a potential clinical marker for vitiligo" 174 : 1318-1326, 2016

      19 Kim JY, "Impact of high-mobility group box 1 on melanocytic survival and its involvement in the pathogenesis of vitiligo" 176 : 1558-1568, 2017

      20 Medici M, "Identification of novel genetic Loci associated with thyroid peroxidase antibodies and clinical thyroid disease" 10 : e1004123-, 2014

      21 Lang KS, "HLA-A2 restricted, melanocyte-specific CD8(+)T lymphocytes detected in vitiligo patients are related to disease activity and are predominantly directed against MelanA/MART1" 116 : 891-897, 2001

      22 Mockenhaupt M, "Evidence of involvement of CXC-chemokines in proliferation of cultivated human melanocytes" 12 : 597-601, 2003

      23 Laberge G, "Early disease onset and increased risk of other autoimmune diseases in familial generalized vitiligo" 18 : 300-305, 2005

      24 Maouia A, "Differential expression of CXCL9, CXCL10, and IFN-γ in vitiligo and alopecia areata patients" 30 : 259-261, 2017

      25 Gill L, "Comorbid autoimmune diseases in patients with vitiligo : a cross-sectional study" 74 : 295-302, 2016

      26 Ferrari SM, "Circulating CXCL10 is increased in nonsegmental vitiligo, in presence or absence of autoimmune thyroiditis" 16 : 946-950, 2017

      27 Harris JE, "Cellular stress and innate inflammation in organspecific autoimmunity : lessons learned from vitiligo" 269 : 11-25, 2016

      28 Van Raemdonck K, "CXCR3 ligands in disease and therapy" 26 : 311-327, 2015

      29 Wutte N, "CXCL13 and B-cell activating factor as putative biomarkers in systemic sclerosis" 169 : 723-725, 2013

      30 Rashighi M, "CXCL10 is critical for the progression and maintenance of depigmentation in a mouse model of vitiligo" 6 : 223-, 2014

      31 Gey A, "Autoimmune thyroid disease in vitiligo : multivariate analysis indicates intricate pathomechanisms" 168 : 756-761, 2013

      32 van den Boorn JG, "Autoimmune destruction of skin melanocytes by perilesional T cells from vitiligo patients" 129 : 2220-2232, 2009

      33 Speeckaert R, "Alterations of CXCL12in serum of patients with vitiligo" 137 : 1586-1588, 2017

      34 Xing L, "Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition" 20 : 1043-1049, 2014

      35 Campbell JD, "Allergic humans are hyporesponsive to a CXCR3 ligand-mediated Th1 immunity-promoting loop" 18 : 329-331, 2004

      더보기

      동일학술지(권/호) 다른 논문

      동일학술지 더보기

      더보기

      분석정보

      View

      상세정보조회

      0

      Usage

      원문다운로드

      0

      대출신청

      0

      복사신청

      0

      EDDS신청

      0

      동일 주제 내 활용도 TOP

      더보기

      주제

      연도별 연구동향

      연도별 활용동향

      연관논문

      연구자 네트워크맵

      공동연구자 (7)

      유사연구자 (20) 활용도상위20명

      인용정보 인용지수 설명보기

      학술지 이력

      학술지 이력
      연월일 이력구분 이력상세 등재구분
      2023 평가예정 해외DB학술지평가 신청대상 (해외등재 학술지 평가)
      2020-01-01 평가 등재학술지 유지 (해외등재 학술지 평가) KCI등재
      2010-01-01 평가 등재학술지 선정 (등재후보2차) KCI등재
      2009-01-01 평가 등재후보 1차 PASS (등재후보1차) KCI등재후보
      2007-01-01 평가 SCOPUS 등재 (신규평가) KCI등재후보
      더보기

      학술지 인용정보

      학술지 인용정보
      기준연도 WOS-KCI 통합IF(2년) KCIF(2년) KCIF(3년)
      2016 1.11 0.23 0.72
      KCIF(4년) KCIF(5년) 중심성지수(3년) 즉시성지수
      0.67 0.48 0.376 0.03
      더보기

      이 자료와 함께 이용한 RISS 자료

      나만을 위한 추천자료

      해외이동버튼